Evidence map›Paper›PMID 39195225›Full record

ArticleCells2024

Cancer-Associated-Fibroblast-Mediated Paracrine and Autocrine SDF-1/CXCR4 Signaling Promotes Stemness and Aggressiveness of Colorectal Cancers.

Chao-Yang Chen, Shih-Hsien Yang, Ping-Ying Chang, Su-Feng Chen, Shin Nieh, Wen-Yen Huang, Yu-Chun Lin, Oscar Kuang-Sheng Lee

Abstract read
In one paragraph

Article in Cells, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Molecules (Basel, Switzerland) · 2026
    Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Chao-Yang ChenDivision of Colon and Rectal Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei 11490, Taiwan.ORCID 0000-0002-2246-7635
Shih-Hsien YangGraduate Institute of Medical Sciences, National Defense Medical Center, Taipei 11490, Taiwan.
Ping-Ying ChangDivision of Hematology-Oncology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei 11490, Taiwan.
Su-Feng ChenDepartment of Dentistry, School of Dentistry, China Medical University, Taichung 40433, Taiwan.
Shin NiehDepartment of Pathology, Tri-Service General Hospital, National Defense Medical Center, Taipei 11490, Taiwan.
Wen-Yen HuangDepartment of Radiation Oncology, Tri-Service General Hospital, National Defense Medical Center, Taipei 11490, Taiwan.
Yu-Chun LinDepartment of Pathology, Tri-Service General Hospital, National Defense Medical Center, Taipei 11490, Taiwan.
Oscar Kuang-Sheng LeeInstitute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei 11221, Taiwan.ORCID 0000-0001-5232-5374

Funding

Ministry of Science and Technology 108-2923-B-010-002-MY3Ministry of Science and Technology 110-2314-B-A49A-504-MY3Ministry of Science and Technology 110-2923-B-A49A-501-MY3Ministry of Science and Technology 111-2321-B-A49-011Tri-Service General Hospital D113082Tri-Service General Hospital E112222
6 · The paper itself

Abstract

Colorectal cancer (CRC) is a leading cause of cancer mortality worldwide, and cancer-associated fibroblasts (CAFs) play a major role in the tumor microenvironment (TME), which facilitates the progression of CRC. It is critical to understand how CAFs promote the progression of CRC for the development of novel therapeutic approaches. The purpose of this study was to understand how CAF-derived stromal-derived factor-1 (SDF-1) and its interactions with the corresponding C-X-C motif chemokine receptor 4 (CXCR4) promote CRC progression. Our study focused on their roles in promoting tumor cell migration and invasion and their effects on the characteristics of cancer stem cells (CSCs), which ultimately impact patient outcomes. Here, using in vivo approaches and clinical histological samples, we analyzed the influence of secreted SDF-1 on CRC progression, especially in terms of tumor cell behavior and stemness. We demonstrated that CAF-secreted SDF-1 significantly enhanced CRC cell migration and invasion through paracrine signaling. In addition, the overexpression of SDF-1 in CRC cell lines HT29 and HCT-116 triggered these cells to generate autocrine SDF-1 signaling, which further enhanced their CSC characteristics, including those of migration, invasion, and spheroid formation. An immunohistochemical study showed a close relationship between SDF-1 and CXCR4 expression in CRC tissue, and this significantly affected patient outcomes. The administration of AMD3100, an inhibitor of CXCR4, reversed the entire phenomenon. Our results strongly suggest that targeting this signaling axis in CRC is a feasible approach to attenuating tumor progression, and it may, therefore, serve as an alternative treatment method to improve the prognosis of patients with CRC, especially those with advanced, recurrent, or metastatic CRC following standard therapy.

Indexed as

Autocrine CommunicationCancer-Associated FibroblastsCell MovementChemokine CXCL12Colorectal NeoplasmsNeoplastic Stem CellsParacrine CommunicationReceptors, CXCR4Signal TransductionAnimalsCell Line, TumorFemaleHCT116 CellsHT29 CellsHumansMaleChemokine CXCL12CXCL12 protein, humanCXCR4 protein, humanReceptors, CXCR4cancer-associated fibroblasts (CAFs)cancer stem cells (CSCs)C-X-C motif chemokine receptor 4 (CXCR4)stromal-derived factor-1 (SDF-1)tumor microenvironment (TME)

Identifiers

PMID39195225
PMCPMC11352219

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.